샘플 요청 목록

 카트 문의
시장보고서
상품코드
1857291

세계의 항응고제 시장

Anticoagulants
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 196 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항응고제 시장은 2030년까지 737억 달러에 도달

2024년에 438억 달러로 추정되는 항응고제 세계 시장은 2024-2030년의 분석 기간에 CAGR 9.1%로 성장하여 2030년에는 737억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 경구 항응고제는 CAGR 9.9%를 나타내고, 분석 기간 종료시에는 463억 달러에 이를 것으로 예측됩니다. 주사용 항응고제 부문의 성장률은 분석 기간중 CAGR 7.8%로 추정됩니다.

미국 시장은 112억 달러로 추정, 중국은 CAGR13.7%로 성장 예측

미국의 항응고제 시장은 2024년에 112억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 197억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 13.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 4.2%와 7.7%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 5.3%를 보일 것으로 예측됩니다.

세계의 항응고제 시장 - 주요 동향과 성장요인 정리

항응고제는 어떻게 작동하며 왜 필수적인가?

항응고제는 심부정맥혈전증(DVT), 폐색전증(PE), 심방세동(AF) 등 혈전색전성 질환의 예방과 치료에 중요한 역할을 합니다. 이러한 약물은 혈액 응고 과정을 억제하고 혈관을 막고 뇌졸중이나 심장마비 등 심각한 건강 합병증을 유발할 수 있는 혈전 형성을 방지합니다. 항응고제에는 와파린과 같은 비타민 K 길항제, 리바록사반이나 아픽사반과 같은 직접 경구용 항응고제(DOACs), 헤파린이나 저분자 헤파린(LMWHs)과 같은 주사제가 있습니다. 항응고제의 선택은 특정 병력, 환자의 특성, 출혈성 합병증 위험에 따라 달라지는 경우가 많습니다. 항응고제는 혈전색전증과 관련된 이환율과 사망률을 감소시키고 환자의 예후를 크게 개선할 수 있기 때문에 현대 의학에서 항응고제는 필수적인 요소입니다.

항응고 치료의 최신 기술 혁신은 무엇인가?

최근 항응고 요법은 특히 경구용 직접 작용 항응고제(DOAC)의 개발로 큰 혁신을 이루었습니다. 정기적인 혈액 모니터링과 식이 제한이 필요한 와파린과 같은 기존 항응고제와 달리 DOAC는 예측 가능한 약동학, 고정된 용량, 약물-음식 상호작용이 적다는 장점이 있습니다. 이러한 장점으로 인해 DOAC는 임상의와 환자들 사이에서 인기 있는 선택이 되고 있습니다. 또한, 다비가트란에 대한 이달시주맙과 인자 Xa 억제제에 대한 안덱사넷알파와 같은 DOAC에 대한 특이적 역전제의 도입은 출혈성 합병증 관리에 대한 우려를 해결하고 이들 약물의 안전성 프로파일을 더욱 향상시키고 있습니다. 전달 메커니즘 영역에서도 혁신이 일어나고 있으며, 환자의 순응도와 치료 효과를 향상시키기 위한 서방형 제제 및 피하 투여 경로에 대한 연구가 진행되고 있습니다. 이러한 발전은 항응고 치료의 역동적인 특성과 임상적 요구를 충족시키기 위한 끊임없는 진화를 강조합니다.

시장 동향은 항응고제 사용에 어떤 영향을 미쳤는가?

시장 동향은 항응고제 사용과 시장 개척에 큰 영향을 미치고 있습니다. 심방세동, 정맥혈전색전증 등 항응고 요법을 필요로 하는 질환의 유병률은 나이가 들수록 증가하기 때문에 세계 인구의 고령화는 큰 원동력이 되고 있습니다. 개인 맞춤형 의료의 추진도 항응고제 시장에 영향을 미치고 있으며, 유전적 요인, 생활습관, 건강 요인에 따라 환자 개개인프로파일에 맞는 치료가 중요시되고 있습니다. 이러한 추세는 약리유전체학의 발전에 힘입어 특정 항응고 요법이 효과가 있는 환자나 용량 조절이 필요한 환자를 식별하는 데 도움이 되고 있습니다. 또한, 전 세계 의료 시스템이 비용 효율성과 의료 관련 합병증 감소에 초점을 맞추고 있기 때문에 안전성 프로파일이 우수하고 모니터링이 덜 필요한 항응고제가 선호되고 있습니다. 경쟁 환경은 현재 진행 중인 연구개발 활동으로 인해 더욱 치열해지고 있으며, 제약사들은 미충족된 임상적 요구를 충족시키기 위해 새로운 항응고 화합물 및 병용요법에 투자하고 있습니다.

항응고제 시장의 성장을 가속하는 요인은 무엇인가?

항응고제 시장의 성장은 몇 가지 요인에 의해 초래됩니다. 약물 개발 및 약물 전달 기술의 발전으로 보다 효과적이고 안전한 항응고제의 선택이 증가하여 다양한 임상 현장에서의 사용이 확대되고 있습니다. 심혈관 질환 및 혈전색전증 유병률 증가, 특히 고령화로 인해 항응고요법에 대한 수요가 크게 증가하고 있습니다. 또한, 수술 전후에 항응고 요법이 필요한 최소 침습 수술로의 전환이 시장을 견인하고 있습니다. 개인 맞춤형 의료와 약리유전체학이 부상함에 따라 보다 표적화되고 효과적인 항응고제를 사용할 수 있게 되어 환자 결과를 개선하고 채택을 촉진하고 있습니다. 또한, 고위험군 환자에게 항응고제의 예방적 사용을 옹호하는 의료 정책 및 가이드라인이 시장 침투를 촉진하고 있습니다. 또한, DOACs의 역류방지제 개발로 안전성에 대한 우려가 완화되어 보다 폭넓은 사용이 촉진되고 있습니다. 이러한 요인들은 지속적인 연구와 기술 혁신과 결합하여 항응고제 시장의 강력한 성장을 가속하고 있습니다.

부문

약제 클래스(NOACs, Xarelto, Heparin &LMWH, Vitamin K Antagonist, 기타 약제 클래스별);투여 경로(경구 항응고제, 주사 항응고제);용도(심방세동, 뇌졸중, 폐색전증(PE), 심부정맥 혈전증(DVT),기타 용도).

조사 대상 기업 예

  • Abbott India Limited
  • Aspen Holdings
  • Bayer Healthcare AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Mitsubishi Tanabe Pharma Corp.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.11.10

Global Anticoagulants Market to Reach US$73.7 Billion by 2030

The global market for Anticoagulants estimated at US$43.8 Billion in the year 2024, is expected to reach US$73.7 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Oral Anticoagulant, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$46.3 Billion by the end of the analysis period. Growth in the Injectable Anticoagulant segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Billion While China is Forecast to Grow at 13.7% CAGR

The Anticoagulants market in the U.S. is estimated at US$11.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.7 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Anticoagulants Market - Key Trends and Drivers Summarized

How Do Anticoagulants Work and Why Are They Essential?

Anticoagulants, often referred to as blood thinners, play a critical role in the prevention and treatment of thromboembolic disorders, which include conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF). These medications work by interfering with the blood's clotting process, preventing the formation of clots that can obstruct blood vessels and lead to serious health complications such as strokes or heart attacks. There are several classes of anticoagulants, including vitamin K antagonists like warfarin, direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban, and injectable options like heparin and low molecular weight heparins (LMWHs). The choice of anticoagulant often depends on the specific medical condition, patient characteristics, and the risk of bleeding complications. Anticoagulants are essential in modern medicine for their ability to reduce morbidity and mortality associated with thromboembolic events, significantly improving patient outcomes.

What Are the Latest Innovations in Anticoagulant Therapy?

Recent years have seen substantial innovations in anticoagulant therapy, particularly with the development of direct oral anticoagulants (DOACs). Unlike traditional anticoagulants like warfarin, which require regular blood monitoring and dietary restrictions, DOACs offer the advantages of predictable pharmacokinetics, fixed dosing, and fewer drug-food interactions. These benefits have made DOACs a popular choice among clinicians and patients alike. Additionally, the introduction of specific reversal agents for DOACs, such as idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors, has addressed concerns regarding the management of bleeding complications, further enhancing the safety profile of these drugs. Innovations are also occurring in the realm of delivery mechanisms, with research exploring extended-release formulations and subcutaneous administration routes to improve patient compliance and therapeutic efficacy. These advancements underscore the dynamic nature of anticoagulant therapy and its continuous evolution to meet clinical needs.

How Are Market Trends Influencing Anticoagulant Usage?

Market trends are significantly influencing the usage and development of anticoagulants. The aging global population is a major driver, as the prevalence of conditions requiring anticoagulation, such as atrial fibrillation and venous thromboembolism, increases with age. The push towards personalized medicine is also impacting the anticoagulant market, with a growing emphasis on tailoring treatment to individual patient profiles based on genetic, lifestyle, and health factors. This trend is supported by advancements in pharmacogenomics, which are helping to identify patients who may benefit from specific anticoagulant therapies or require dosage adjustments. Additionally, healthcare systems worldwide are focusing on cost-effectiveness and the reduction of healthcare-associated complications, leading to an increased preference for anticoagulants with superior safety profiles and lower monitoring requirements. The competitive landscape is further shaped by ongoing research and development activities, with pharmaceutical companies investing in novel anticoagulant compounds and combination therapies to address unmet clinical needs.

What Factors Are Driving Growth in the Anticoagulants Market?

The growth in the anticoagulants market is driven by several factors. Technological advancements in drug development and delivery have resulted in more effective and safer anticoagulant options, expanding their use across various clinical settings. The increasing prevalence of cardiovascular diseases and thromboembolic disorders, particularly in aging populations, is generating significant demand for anticoagulant therapies. Additionally, the shift towards minimally invasive surgical procedures, which often necessitate perioperative anticoagulation, is boosting the market. The rise of personalized medicine and pharmacogenomics is enabling more targeted and effective use of anticoagulants, improving patient outcomes and driving adoption. Furthermore, healthcare policies and guidelines advocating for the prophylactic use of anticoagulants in high-risk patient groups are enhancing market penetration. The development of reversal agents for DOACs has also mitigated safety concerns, encouraging broader usage. These factors, combined with continuous research and innovation, are propelling the robust growth of the anticoagulants market.

SCOPE OF STUDY:

The report analyzes the Anticoagulants market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist, Other Drug Classes); Route of Administration (Oral Anticoagulant, Injectable Anticoagulant); Application (Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott India Limited
  • Aspen Holdings
  • Bayer Healthcare AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Mitsubishi Tanabe Pharma Corp.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Anticoagulants - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Aging Population Expands Addressable Market Opportunity for Anticoagulant Therapies
    • Pharmacogenomics and Personalized Medicine Strengthen Business Case for Tailored Anticoagulant Treatment
    • Introduction of Reversal Agents for DOACs Generates Demand and Enhances Safety Profiles
    • Increased Prevalence of Cardiovascular Diseases Drives Adoption of Anticoagulant Therapies
    • Shift Towards Minimally Invasive Procedures Spurs Growth in Perioperative Anticoagulation
    • Healthcare Policies and Guidelines Advocating Prophylactic Use Propel Market Growth
    • Development of Extended-Release Formulations and Subcutaneous Administration Expands Market Opportunities
    • Rising Awareness of Thromboembolic Disorders Throws the Spotlight on Preventative Anticoagulation
    • Increasing Use of Anticoagulants in High-Risk Patient Groups Generates Demand for Tailored Therapies
    • Consumer Preferences for Convenience and Safety in Medication Drives Adoption of DOACs and Novel Anticoagulants
    • Challenges in Managing Bleeding Complications Create Opportunities for Reversal Agents and New Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for NOACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for NOACs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for NOACs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Xarelto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Xarelto by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Xarelto by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Heparin & LMWH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Heparin & LMWH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Heparin & LMWH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Vitamin K Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Vitamin K Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Vitamin K Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oral Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Oral Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Oral Anticoagulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Injectable Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Injectable Anticoagulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Injectable Anticoagulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Stroke by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Stroke by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Deep Vein Thrombosis (DVT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Deep Vein Thrombosis (DVT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Anticoagulants Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Anticoagulants by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Anticoagulants by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Anticoagulants by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Anticoagulants by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Anticoagulants Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Anticoagulants by Drug Class - NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Anticoagulants by Drug Class - Percentage Breakdown of Value Sales for NOACs, Xarelto, Heparin & LMWH, Vitamin K Antagonist and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Anticoagulants by Route Of Administration - Oral Anticoagulant and Injectable Anticoagulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Anticoagulants by Route Of Administration - Percentage Breakdown of Value Sales for Oral Anticoagulant and Injectable Anticoagulant for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Anticoagulants by Application - Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Anticoagulants by Application - Percentage Breakdown of Value Sales for Atrial Fibrillation, Stroke, Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT) and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제